Melanocyte protein Pmel 17 precursor (44-59)

Melanocyte protein Pmel 17 precursor (44-59) is a synthetic peptide fragment derived from the Pmel 17 protein, a key structural component involved in the biogenesis of melanosomes within melanocytes. This peptide segment encompasses amino acids 44 to 59 of the precursor molecule, a region implicated in the early stages of melanosome maturation and fibril formation. As an important model in pigment cell biology, the sequence offers researchers a valuable tool for dissecting the molecular mechanisms underlying melanosome assembly, amyloid-like fibril formation, and pigment synthesis. Its defined structure and biochemical relevance make it a versatile reagent for studies in protein-protein interactions, post-translational modifications, and the broader context of organelle biogenesis in pigment-producing cells.

Melanosome biogenesis research: As a defined segment of the Pmel 17 protein, this peptide serves as a critical probe for investigating the molecular events that drive the formation and maturation of melanosomes. By providing a specific sequence involved in the early stages of fibril assembly, the peptide enables researchers to examine the structural transitions and intermolecular interactions that underpin the development of functional pigment organelles. In vitro studies utilizing this fragment can help delineate the sequence determinants necessary for amyloid fibril nucleation, shedding light on the unique physiological role of functional amyloids in melanocytes.

Protein aggregation and amyloid studies: The 44-59 sequence of Pmel 17 is of particular interest in the context of physiological amyloid formation, as the parent protein is one of the few examples where amyloidogenesis serves a beneficial cellular function. Researchers can employ this peptide to model the aggregation behavior of Pmel 17, analyze the kinetics and morphology of fibril formation, and compare these properties to pathogenic amyloids found in neurodegenerative disorders. Such studies provide insights into sequence-specific factors that govern amyloid assembly, stability, and cellular compatibility, contributing to the broader understanding of protein aggregation phenomena.

Antibody epitope mapping: The defined amino acid sequence of the peptide makes it an ideal substrate for mapping antibody binding sites specific to Pmel 17. By using the 44-59 peptide in immunoassays, scientists can characterize monoclonal and polyclonal antibody specificity, determine epitope accessibility, and optimize antibody reagents for use in pigment cell research. This application is particularly valuable for the development of diagnostic tools, flow cytometry panels, and imaging reagents targeting melanocyte lineage markers.

Peptide-based assay development: The fragment can be incorporated into a range of biochemical and cell-based assays designed to monitor protein interactions, enzymatic modifications, or peptide uptake in melanocyte systems. Its sequence specificity allows for the design of quantitative assays that assess the activity of processing enzymes, the impact of post-translational modifications, or the efficacy of peptide delivery strategies. Such assays support high-throughput screening efforts or mechanistic studies aimed at elucidating the regulation of Pmel 17 function and melanosome dynamics.

Structural and biophysical characterization: The Melanocyte protein Pmel 17 precursor (44-59) peptide provides a tractable model for structural studies using techniques such as NMR spectroscopy, circular dichroism, or X-ray crystallography. Researchers can leverage the fragment to investigate secondary structure propensities, folding dynamics, and interaction motifs relevant to fibril formation and protein assembly. These insights are instrumental in understanding how specific sequence elements contribute to the functional architecture of melanosomes and may guide the rational design of modulators that influence pigment cell physiology.

1. Myotropic activity of allatostatins in tenebrionid beetles

2. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

3. Cationic cell-penetrating peptides are potent furin inhibitors

4. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

5. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction